FDA Peptide Status 2026: Compounding, Category 2, and What It Means for Research

A current snapshot of the regulatory landscape, the 503A and 503B pathways, and what 2026 changed

The peptide regulatory landscape changed materially in September 2023 and has continued evolving through 2026. If you're reading a peptide article from 2022, the legal framework it describes is largely outdated.

This is the current snapshot of what FDA does and does not allow, what changed, and what's likely to change next.

The September 2023 Category 2 listing

The FDA maintains a list of substances that compounding pharmacies can use to prepare medications. Substances on the "503A bulk drug substance" list are permitted. Substances on Category 2 are essentially prohibited from compounding because the FDA has determined that the available safety information is insufficient to support patient use.

In September 2023, the FDA placed several investigational peptides on Category 2:

• BPC-157 (Body Protection Compound 157)
• Thymosin Beta-4 / TB-500
• Selank
• Semax
• Epitalon
• Several others under the GHRP family (GHRP-6, GHRP-2 in some forms)

The practical effect: 503A compounding pharmacies stopped supplying these compounds to patients. The legal supply in the US contracted dramatically.

What this did NOT do

The Category 2 listing does not make peptides illegal to possess. It restricts pharmacy compounding for human use. Several distinctions matter:

• Possession of a research peptide is not in itself a federal offense (though state laws vary)
• Use in formal clinical research with an IND is unaffected
• Veterinary use under appropriate licensing is unaffected (though state veterinary boards have their own rules)
• FDA-approved peptides (semaglutide, tirzepatide, oxytocin, etc.) are unaffected

The compounded GLP-1 question

The most consequential 2024-2026 regulatory question has been compounded semaglutide and tirzepatide. During the brand-name shortages of 2023-2024, compounding pharmacies were permitted to prepare alternatives under FDA shortage exceptions. As Novo Nordisk and Eli Lilly resolved supply issues, the FDA removed the shortage designation, and compounded versions were largely phased out — though aggressive lobbying from compounding interests continues.

The current position (as of April 2026): compounded semaglutide and tirzepatide are permitted only for specific allergen or dose customization needs, not as a general workaround for brand pricing. Many compounding pharmacies are operating in a gray zone, and the FDA has issued multiple warning letters.

FDA-approved peptide drugs available in 2026

The list of FDA-approved peptide drugs continues to grow. Currently approved:

• Semaglutide: Ozempic (T2D, 2017), Wegovy (obesity, 2021), Rybelsus (oral, 2019)
• Tirzepatide: Mounjaro (T2D, 2022), Zepbound (obesity, 2023)
• Liraglutide: Victoza (T2D), Saxenda (obesity)
• Dulaglutide: Trulicity (T2D)
• Afamelanotide: Scenesse (erythropoietic protoporphyria)
• Octreotide: Sandostatin (acromegaly, neuroendocrine tumors)
• Teriparatide: Forteo (osteoporosis)
• Synthetic oxytocin: Pitocin and others
• Insulin and insulin analogs (technically peptides)
• GLP-1 / GIP / glucagon triple agonists: retatrutide expected 2026-2027

The international picture

FDA decisions don't bind other regulators. The European Medicines Agency has its own positions. Several peptides approved abroad are not approved in the US — Thymosin Alpha-1 is the canonical example, approved in 35+ countries for hepatitis B/C and immunomodulation but not in the US.

Russian and Chinese regulatory frameworks have approved Selank, Semax, Cerebrolysin and others. These remain unavailable as approved drugs in the US.

This international fragmentation has practical consequences: medical tourism for peptide therapy is a growing phenomenon, and online suppliers operating from non-US jurisdictions are the main gray-market source.

Where this is heading

Several predictions seem reasonably safe:

FDA-approved peptide pipeline will continue to expand. Triple-receptor agonists, oral peptides, and weekly/monthly formulations are all in late development. The post-semaglutide regulatory framework has been streamlined for incretin-class drugs.

Compounding restrictions will persist. The FDA's general posture toward investigational peptide compounding has hardened over 2024-2026. Reversal of the Category 2 listings is unlikely without significant new safety data.

State-level enforcement will increase. Texas, California, and Florida have taken different positions on peptide-related practices. Expect more state attorney general action against marketers and clinics making improper claims.

Telehealth peptide clinics face increased scrutiny. The model of remote prescribing for peptides has come under FDA and DOJ attention. Several large operations have settled or shut down.

The bottom line: the regulatory environment for peptides in 2026 is more restrictive than in 2022 but more sophisticated. FDA-approved peptides are rapidly expanding. Investigational peptides face tighter constraints. The educational and research ecosystem continues — what has changed is that gray-market supply chains have less legal cover.